Related coverage linked through entity extraction aliases.
May 14, 2026
The FDA cleared neuromodulation devices from Epineuron, Aneuvo and Encora Therapeutics. The products address peripheral nerve surgery, spinal cord injury neurorehabilitation and essential tremor.
Apr 24, 2026
A preclinical study in Precision Clinical Medicine found that luteolin and astragaloside IV improved recovery after severe spinal cord injury in cell and rat models. The combined treatment reduced oxidative stress and neuroinflammation and improved motor function over five weeks.
Apr 09, 2026
AbbVie updated its completed Phase 2 elezanumab study in acute traumatic cervical spinal cord injury. The placebo-controlled trial began in March 2020 and its latest public update was posted on February 9, 2026.
Feb 13, 2026
Scientists at Northwestern University developed human spinal cord organoids that accurately replicate injury responses including cell death, inflammation, and glial scarring. Testing showed a "dancing molecules" therapy significantly reduced scarring and promoted nerve regrowth.
